Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 2/20 | 0.46 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.42 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | P2RY12 | Q9H244 | 4/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6809258 | 0.87 | TGM2 (0.46) | TGM2ITGB3ITGA2BTDP1P2RY12 | |
| Hydrochloric Acid SCHEMBL6809256 | 0.81 | DPP7 (0.38) | TGM2 | |
| SCHEMBL4911293 | 0.77 | TLR2 (0.52) | TGM2ITGB3ITGA2BHDAC1HDAC8 | |
| SCHEMBL6389169 | 0.75 | ITGB3 (0.54) | TGM2ITGB3ITGA2BHDAC1HDAC8 | |
| SCHEMBL4906241 | 0.75 | ITGB3 (0.54) | TGM2ITGB3ITGA2BHDAC1HDAC8 | |
| SCHEMBL4911413 | 0.74 | ITGB3 (0.50) | TGM2ITGB3ITGA2BHDAC1HDAC8 | |
| SCHEMBL4909415 | 0.73 | ITGB3 (0.43) | TGM2ITGB3ITGA2BHDAC1HDAC8 | |
| SCHEMBL6809984 | 0.73 | ITGB3 (0.47) | TGM2ITGB3ITGA2BTDP1P2RY12 | |
| SCHEMBL1754974 | 0.71 | BCHE (0.54) | MEN1KMT2A | |
| SCHEMBL5350152 | 0.71 | TGM2 (0.47) | TGM2ITGB3ITGA2BTDP1P2RY12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040235752-A1 | 3-fluoro-pyrrolidines as antidiabetic agents | FERRING B.V. (NL) | 2004-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235752-A1 | 3-fluoro-pyrrolidines as antidiabetic agents | DPP4, DPP7, DPP3 | TGM2 1011/4885ITGB3 3366/4885ITGA2B 4014/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.